[G24-23] Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Second Addendum to Project A24-46
Last updated 17.10.2024
Project no.:
G24-23
Commission:
Commission awarded on 10.09.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Application field:
Cancer
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
DOI:
https://doi.org/10.60584/G24-23
| Project no. | Title | Status |
|---|---|---|
| A24-46 | Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to § 35a Social Code Book V | Commission completed |
| A24-93 | Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Addendum to Project A24-46 | Commission completed |
Federal Joint Committee (G-BA)
2024-10-17 A G-BA decision was published.